drug
(trospium chloride + xanomeline tartrate)
Marketedupdated 3mo agoby Bristol-Myers Squibb Co
Approvedcommunity read0 votes
indications
investigational
Schizophrenia
all catalysts(0)
nothing on the calendar yet
Patent cliff
source: FDA Orange Bookfirst barrier falls
Sep 26, 2029
~3.1 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (33)
- Oct 29, 2039formulationUS 12558317
- Oct 29, 2039formulationUS 12558317
- Oct 29, 2039formulationUS 12558317
- Sep 27, 2039formulationUS 10925832
- Sep 27, 2039formulationUS 10925832
- Sep 27, 2039formulationUS 10925832
- Sep 27, 2039formulationUS 10933020
- Sep 27, 2039formulationUS 10933020
- Sep 27, 2039formulationUS 10933020
- Sep 27, 2039method-of-use (U-3513)US 11452692
- Sep 27, 2039method-of-use (U-3513)US 11452692
- Sep 27, 2039method-of-use (U-3513)US 11452692
- Sep 27, 2039method-of-use (U-3513)US 11471413
- Sep 27, 2039method-of-use (U-3513)US 11471413
- Sep 27, 2039method-of-use (U-3513)US 11471413
- Sep 27, 2039formulationUS 11890378
- Sep 27, 2039formulationUS 11890378
- Sep 27, 2039formulationUS 11890378
- Jul 21, 2030formulationUS 102386433.9y
- Jul 21, 2030formulationUS 102386433.9y
- Jul 21, 2030formulationUS 102386433.9y
- Jul 21, 2030method-of-use (U-3513)US 102653113.9y
- Jul 21, 2030method-of-use (U-3513)US 102653113.9y
- Jul 21, 2030method-of-use (U-3513)US 102653113.9y
- Jul 21, 2030method-of-use (U-3513)US 103691433.9y
- Jul 21, 2030method-of-use (U-3513)US 103691433.9y
- Jul 21, 2030method-of-use (U-3513)US 103691433.9y
- Jul 21, 2030formulationUS 103691443.9y
- Jul 21, 2030formulationUS 103691443.9y
- Jul 21, 2030formulationUS 103691443.9y
- Jul 21, 2030method-of-use (U-3513)US 106953393.9y
- Jul 21, 2030method-of-use (U-3513)US 106953393.9y
- Jul 21, 2030method-of-use (U-3513)US 106953393.9y
FDA exclusivities (3)
- Sep 26, 2029NCENew Chemical Entity (5y)3.1y
- Sep 26, 2029NCENew Chemical Entity (5y)3.1y
- Sep 26, 2029NCENew Chemical Entity (5y)3.1y
News(10)
- As BMS’ Cobenfy struggles to gain traction, MapLight knocks on the doorDespite the recent emergence of a new drug class, schizophrenia remains one of the most challenging neuropsychiatric diseases to treat—and Cobenfy's first steps into the market indicate there is st…biospace · 1d ago
- As portfolio erodes, BMS stands to gain a lot from rumored AstraZeneca mergerWhile both drugmakers face looming patent cliffs, analysts say joining forces could help Bristol Myers Squibb replenish its eroding portfolio—while the strategic case for AstraZeneca seems to be mo…biospace · 7d ago
- An AstraZeneca-Bristol Myers megamerger? Wall Street isn’t thrilled.In fact, the former lost tens of billions of dollars in market value following reports of a potential tie-up between the pharmaceutical giants.biopharma_dive · 8d ago
- Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOsSanofi wants to broaden the company’s productive partnership with Regeneron, its CEOs said. Elsewhere, Bristol Myers delayed two anticipated study readouts and a Shionogi-backed startup went public.biopharma_dive · 11d ago
- BMS’ ‘big beat’ clouded by Cobenfy, heart disease data delaysStrong quarterly results are prompting Bristol Myers Squibb to lift its 2026 outlook, though the company is facing another delay for key Cobenfy Alzheimer’s data and a pushed-back readout for milve…biospace · 12d ago
- Bristol Myers delays Cobenfy Alzheimer’s psychosis readout again amid another quarterly beatInvestors awaiting Bristol Myers Squibb’s key Alzheimer’s psychosis readout for Cobenfy and atrial fibrillation data for milvexian will have to wait a little longer.fiercebiotech · 12d ago
- MapLight CEO on what investors missed in the biotech’s schizophrenia dataThough positive, mid-stage study results erased about two-thirds of the biotech's market value this week. But Christopher Kroeger sees MapLight's drug as competitive based on the "totality of data."biopharma_dive · 12d ago
- MapLight dives despite positive data for schizophrenia drugShares fell more than 66% Monday morning, which analysts suspect is due to investors seeing the data as not competitive with Bristol Myers' Cobenfy.biopharma_dive · 15d ago
- MapLight’s schizophrenia pill remains in Cobenfy’s shadow after mixed Phase 2 readoutWhile MapLight Therapeutics’ oral schizophrenia candidate reached the main endpoint of a Phase 2 trial, analysts say Bristol Myers Squibb's Cobenfy is likely to hold its market share.biospace · 15d ago
- MapLight shares sink on mixed phase 2 schizophrenia readoutMapLight Therapeutics’ stock plummeted more than 60% this morning after the neuro outfit dropped mixed results for a phase 2 trial of its experimental schizophrenia treatment.fiercebiotech · 15d ago
Data sources
last refreshed 38m ago
Found something off?
comments(0)
5-min edit window · permanent after that